Olutasidenib is approved by FDA for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation

Share This Post

Dec 2022: Olutasidenib (Rezlidhia) capsules were approved by the Food and Drug Administration (FDA) for adult patients with relapsed or resistant acute myeloid leukaemia (AML) who have a susceptible IDH1 mutation as identified by an FDA-approved test.

The Abbott RealTime IDH1 Assay was just given FDA approval to help doctors choose patients to receive olutasidenib.

Study 2102-HEM-101 (NCT02719574), an open-label, single-arm, multicenter clinical trial involving 147 adult patients who had relapsed or refractory AML and an IDH1 mutation validated by the aforementioned assay, served as the foundation for the approval. Up until the onset of the disease, the occurrence of intolerable toxicity, or a hematopoietic stem cell transplant, olutasidenib was administered orally, 150 mg twice daily. The typical length of treatment was 4.7 months (range: 0.1 – 26 months). Following olutasidenib treatment, sixteen patients (11%) had hematopoietic stem cell transplantation.

The rate of complete remission (CR) plus complete remission with partial hematologic recovery (CRh), the length of CR+CRh, and the rate of transition from dependence on transfusions to independence were used to determine efficacy. The CR+CRh rate, which includes 32% CR and 2.7% CRh, was 35% (95% confidence interval [CI]: 27%, 43%). In the range of 0.9 to 5.6 months, the median time to CR+CRh was 1.9 months, and the median time to CR+CRh itself was 25.9 months (95% CI: 13.5 months, not attained).

During any 56-day post-baseline period, 29 (34%) of the 86 patients who were dependent on red blood cell (RBC) and/or platelet transfusions at baseline were no longer dependent. 39 (64%) of the 61 patients who were transfusion-free for both RBC and platelet transfusions at baseline continued to be so for any 56-day post-baseline period.

Nausea, fatigue/malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhoea, and transaminitis were the most frequent side effects (20%). A Boxed Warning in the prescribing instructions warns patients and medical professionals about the possibility of the potentially deadly differentiation syndrome.

Up until illness progression or intolerable toxicity, 150 mg of olutasidenib should be given orally twice daily on an empty stomach (at least 1 hour before or 2 hours after a meal). Treatment is advised for at least 6 months to allow for a clinical response in patients whose disease has not progressed or who have not had significant toxicity.


View full prescribing information for Rezlidhia

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form

Start chat
Need help with cancer treatment?

Welcome to CancerFax.

CancerFax is the most trusted international patient facilitator working with top cancer hospital's in the world like MD Anderson, Dana Farber, Asan, NCC Japan, Sheba, Beijing Cancer Institute and Apollo to bring you best of therapies and drugs.

let us know what services would you like to take?

1) Travel abroad for cancer treatment
2) CAR T-Cell therapy treatment
3) Cancer vaccine
4) Online video consultation